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Antifungal activitiesAbstract In the present study a new series of 3-hydroxy-7-isocyano-6-oxo-8-phenyl-2-(substi-
tutedphenyl(piperidin-1-yl)methyl)-6H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-a]-pyridine-9-carbo-
nitrile (5a–j) and (Z)-2-(4-substitutedbenzylidene)-7-isocyano-3,6-dioxo-8-phenyl-3,6-dihydro-2H-
thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbo-nitrile derivatives (4a–j) were synthesized.
The newly synthesized compounds were characterized by IR, 1H NMR, LC–MS mass and C,
H, N analyses. All newly synthesized compounds were screened for their antibacterial (Esche-
richia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes and Klebsiella
pneumoniae) and antifungal (Aspergillus ﬂavus, Aspergillus fumigatus, Candida albicans, Penicillium
marneffei and Trichophyton mentagrophytes) activity. The results revealed that all synthesized
compounds have a signiﬁcant biological activity against the tested microorganisms. Compounds
4a, 4f, 4i, 4j, 5a, 5i and 5j exhibited good antimicrobial activity.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Triazoles are important classes of heterocyclic compounds. In
particular, fused 1,2,4-triazoles express antifungal (El-Hawash
et al., 1999), bactericidal (El-Hawash et al., 1999; Brown and
Iwai, 1979), anxiolytic (Tarzia et al., 1988; Trust and Albrigh,1980), anticonvulsant (Tarzia et al., 1989) or herbicidal (Peig-
nier et al., 1991; Cantegriil et al., 1997) activities and can act as
antidepressants (Sarges et al., 1990). Therefore, versatile and
widely applicable methods for their synthesis are of consider-
able interest. Most methods for the preparation of fused
1,2,4-triazoles are mainly based on hydrazones as precursors.
However, these methods have some restrictions regarding their
applicability and the use of toxic reagents like lead tetraacetate
(Bower and Doyle, 1957; Pollak and Tisler, 1966) and bromine
(Pollak and Tisler, 1966; Gibson, 1963), also the other prod-
ucts were formed in low yield and isolated as salts (Hadi
et al., 1992; Al-Najjar et al., 1996). Many 1,2,4-triazine deriv-
atives are well known to possess biological activities, thus they
have been found to be useful as herbicides (Neunhoeffer, 1978;
Neunhoeffer, 1984). In the last decade they have been screened
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(Abdel-Rahman et al., 1999; Abdel-Rahman et al., 1994;
Abdel-Rahman et al., 1999; Abdel-Rahman, 2001). However
the aza-Wittig reaction is a powerful tool for the synthesis of
ﬁve- to seven-membered nitrogen heterocycles (Takeuchi
et al., 1989; Eguchi and Goto, 1994; Eguchi et al., 1992;
Takeuchi et al., 1989; Molina and Fresneda, 1988; Molina
et al., 1990; Molina and Vilaplana, 1990; Wamhoff and
Schmidt, 1993; Sato et al., 1993; Molina et al., 1990a; Molina
et al., 1990b). Annulation of ring systems with N-heterocycles
by means of an aza-Wittig reaction has recently been widely
utilized because of the availability of functionalized imino-
phosphoranes (Palacios et al., 2007; Eguchi, 2006; Braese
et al., 2005; Eguchi, 2005; Fresneda and Molina, 2004). Many
important monocyclic nitrogen heterocycles such as indole,
pyridine, pyrimidine and isoquinoline derivatives have been
synthesized via the intramolecular aza-Wittig reaction (Takeu-
chi et al., 1989; Eguchi and Goto, 1994; Eguchi et al., 1992;
Takeuchi et al., 1989), as well as by the intermolecular aza-
Wittig reaction followed by electrocyclization, intramolecular
cycloaddition or heterocyclization (Molina and Fresneda,
1988; Molina et al., 1990; Wamhoff and Schmidt, 1993; Sato
et al., 1993; Molina et al., 1990a; Molina et al., 1990b). We
have previously published the synthesis of fused pyrimidines
based on the tandem aza-Wittig annulation strategy (Barsy
and El-Rady, 2006), and as a part of our ongoing studies we
now describe a novel one-pot synthesis of 1,2,4-triazolo[1,5-
a]pyridine and pyrido[1,2-b][1,2,4]triazines derivatives in good
yield.2. Experimental
2.1. Materials and reagents
All reagents and solvents were purchased and used without
further puriﬁcation. Melting points were determined on a Fish-
er–Johns melting point apparatus and are uncorrected. Crude
products were puriﬁed by column chromatography on silica
gel of 60–120 mesh. IR spectra were obtained on a Perkin–
Elmer BX serried FT-IR 5000 spectrometer using KBr pellet.
NMR spectra were recorded on a Varian 300 MHz spectrom-
eter for 1H NMR. The chemical shifts were reported as ppm
down ﬁeld using TMS as an internal standard. LC–MS Mass
spectra were recorded on a MASPEC low resolution mass
spectrometer operating at 70 eV.
2.2. General procedure for the preparation of 1-amino-6-
(triphenylphosphoranylidene-amino)-2-oxo-4-phenyl-1,2-
dihydropyridine-3,5-dicarbonitrile (2)
1-Amino-6-(triphenylphosphoranylideneamino)-2-oxo-4-phenyl
-1,2-dihydro-pyridine-3,5-dicarbonitrileiminophosphorane (2)
were synthesized according to the reported method by the reac-
tion with triphenylphosphine/hexachloroethane and triethyl-
amine reagent system (the Appel method, i.e., the modiﬁed
Kirsanov reaction) (Appel et al., 1970). To a stirred mixture
of 1,6-diamino-2-oxo-4-phenyl-1,2-dihydropyridine-3,5-dicar-
bonitrile 1, (0.5 g, 2.0 mmol), hexachloroethane (0.473 g,
2.0 mmol, 1.0 equiv.) and triphenylphosphine (0.52 g, 2.0 mmol,
1.0 equiv.) in anhydrous benzene (50.0 mL) triethylamine
(0.4 mL, 4.0 mmol, 2.0 equiv.) were added dropwise. The resul-tant solution was heated at reﬂux for 2 h. The mixture was ﬁl-
tered while still hot in order to remove the precipitates and
the ﬁltrate was evaporated under reduced pressure to give a so-
lid product which was crystallized from ethanol as colorless
crystals; yield: 950 mg (95%); mp 170 C, IR (KBr, cm1):
1656 (C‚O), 2210 (C‚N), 3229, 3259 (NH2),
1H NMR
(300 MHz, DMSO-d6): d 7.1–7.8 (m, 20H, Ar-H), 8.9 (s, 2H,
NH2); LC–MS (m/z, %): 511 (M)
+. Anal. Calcd for
C31H22N5OP: C, 72.79; H, 4.34; N,13.69. Found: C, 72.65; H,
4.25; N, 13.57.2.3. Synthesis of 5-oxo-7-phenyl-2-thiol-3,5-dihydro[1,2,4]-
triazolo[1,5-a]pyridine-6,8-dicarbonitrile (3)
To a solution of 1-amino-6-(triphenylphosphoranylideneami-
no)-2-oxo-4-phenyl-1,2-dihydro-pyridine-3,5-dicarbonitrilei-
minophosphorane 2 (0.5 g, 1.0 mmol) in 15 mL of dry toluene
an excess of carbon disulﬁde (7 mL) was added. The reaction
mixture was heated in a closed two-neck round bottom ﬂask
at 100 C for 3 h. The crystals that formed were collected
and crystallized from a mixture of DMF and H2O (1:1) as yel-
low crystals, yield: 240 mg (83%); mp 215 C, IR (KBr, cm1):
1200 (SH), 1655 (C‚O), 2210 (C‚N), 3120 (NH), 1H NMR
(300 MHz, DMSO-d6): d 2.5 (s, 1H, SH), 6.9–7.3 (m, 5H,
Ar-H), 10.3 (s, H, NH); LC–MS (m/z, %): 293 (M)+. Anal.
Calcd for C14H7N5OS: C, 57.33; H, 2.41; N, 23.88. Found:
C, 57.11; H, 2.55; N, 23.57.2.4. Synthesis of (Z)-2-(4-substitutedbenzylidene)-7-isocyano-
3,6-dioxo-8-phenyl-3,6-dihydro-2H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (4)
A mixture of 5-oxo-7-phenyl-2-thiol-3,5-dihydro[1,2,4]-triaz-
olo[1,5-a]pyridine-6,8-dicarbonitrile (3) (5 mmol), aromatic
aldehydes (5 mmol), chloroacetic acid (5 mmol) and fused
sodium acetate (10 mmol) were reﬂuxed in acetic acid/acetic
anhydride (25:5 mL) mixture for 3 h. Then the reaction
mixture was cooled, ﬁltered and crystallized from acetic acid
to give the (Z)-2-(4-substitutedbenzylidene)-7-isocyano-3,6-
dioxo-8-phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triaz-
olo[1,5-a]pyridine-9-carbonitrile 4a–j in 66–89% yields. The
Rf values were measured using benzene/ethyl acetate mix-
ture as an eluent in ratio (9:1). The reaction sequences were
outlined in Scheme 1.2.4.1. (Z)-2-Benzylidene-7-isocyano-3,6-dioxo-8-phenyl-3,6-
dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-
9-carbonitrile (4a)
White solid in a yield of 87%, mp 146–148 C; IR (KBr,
cm1): 3032 (Ar-H), 1730 (C‚O), 1590 (C‚N), 1H NMR
(300 MHz, DMSO-d6): d 8.20 (s, 1H, CH), 7.60–7.55 (m,
2H, Ar-H), 7.45–7.33 (m, 6H, Ar-H), 7.19–7.17 (m, 2H, Ar-
H), LC–MS (m/z, %): 422 (M+1)+. Anal. Calcd for
C23H11N5O2S: C, 64.25; H, 2.55; N, 16.57. Found: C, 65.55;
H, 2.63; N, 16.62.
2.4.2. (Z)-2-(4-Chlorobenzylidene)-7-isocyano-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (4b)
White solid in a yield of 66%, mp 171–172 C; IR (KBr, cm1):
3030 (Ar-H), 1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz,
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138 M. Suresh et al.DMSO-d6): d 7.80 (s, 1H, CH), 7.68–7.66 (m, 2H, Ar-H),
7.44–7.33 (m, 5H, Ar-H), 7.17–7.15 (m, 2H, Ar-H), LC–MS
(m/z, %): 456 (M+1)+. Anal. Calcd for C23H10ClN5O2S: C,
60.76; H, 2.36; N, 15.52. Found: C, 60.60; H, 2.21; N,
15.36.
2.4.3. (Z)-2-(4-Nitrobenzylidene)-7-isocyano-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (4c)
Yellow solid in a yield of 79%, mp 201–202 C; IR (KBr,
cm1): 3050 (Ar-H), 1730 (C‚O), 16,000 (C‚N), 1H NMR
(300 MHz, DMSO-d6): d 8.21–8.20 (m, 2H, Ar-H), 8.03–8.00
(m, 2H, Ar-H), 7.94 (s, 1H, CH), 7.46–7.33 (m, 3H, Ar-H),
7.17–7.15 (m, 2H, Ar-H), LC–MS (m/z, %): 465 (M+1)+.
Anal. Calcd for C23H10N6O4S: C, 59.37; H, 2.29; N, 18.24.
Found: C, 59.23; H, 2.16; N, 18.02.
2.4.4. (Z)-7-Isocyano-2-(4-methoxybenzylidene)-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (4d)
White solid in a yield of 81%, mp 183–184 C; IR (KBr, cm1):
3030 (Ar-H), 1710 (C‚O), 1590 (C‚N), 1H NMR (300 MHz,
DMSO-d6): d 7.80 (s, 1H, CH), 7.46–7.33 (m, 5H, Ar-H), 6.71–
6.70 (m, 2H, Ar-H), 3.06 (s, 3H, OCH3). LC–MS (m/z, %): 452
(M+1)+. Anal. Calcd for C24H13N5O3S: C, 64.12; H, 2.98; N,
15.06. Found: C, 63.85; H, 2.90; N, 15.51.
2.4.5. (Z)-2-(4-(Dimethylamino)benzylidene)-7-isocyano-3,6-
dioxo-8-phenyl-3,6-dihydro-2H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (4e)
Yellow solid in a yield of 69%, mp 203–204 C; IR (KBr,
cm1): 3030 (Ar-H), 1710 (C‚O), 1580 (C‚N), 1H NMR(300 MHz, DMSO-d6): d 7.80 (s, 1H, CH), 7.46–7.33 (m, 5H,
Ar-H), 6.71–6.70 (m, 2H, Ar-H), 3.02 (s, 3H, N(CH3)2). LC–
MS (m/z, %): 465 (M+1)+. Anal. Calcd for C25H16N6O2S:
C, 64.83; H, 3.56; N, 17.89. Found: C, 64.64; H, 3.47; N,
18.07.
2.4.6. (Z)-2-(4-Bromobenzylidene)-7-isocyano-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (4f)
White solid in a yield of 89%, mp 194–195 C; IR (KBr, cm1):
3030 (Ar-H), 1710 (C‚O), 1580 (C‚N), 1H NMR (300 MHz,
DMSO-d6): d 7.80 (s, 1H, CH), 7.68–7.66 (m, 2H, Ar-H), 7.44–
7.33 (m, 5H, Ar-H), 7.17–7.15 (m, 2H, Ar-H). LC–MS (m/z,
%): 502 (M+2)+. Anal. Calcd for C23H10BrN5O2S: C,
55.43; H, 2.22; N, 13.88. Found: C, 55.21; H, 2.01; N, 14.00.
2.4.7. (Z)-Methyl 4-((9-cyano-7-isocyano-3,6-dioxo-8-phenyl-
3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridin-2-ylidene)methyl)benzoate (4g)
White solid in a yield of 68%, mp 165–166 C; IR (KBr, cm1):
3030 (Ar-H), 1760 (OCO), 1730 (C‚O), 1580 (C‚N), 1H
NMR (300 MHz, DMSO-d6): d 7.80 (s, 1H, CH), 7.67–7.66
(m, 2H, CH), 7.49–7.33 (m, 5H, Ar-H), 7.17–7.15 (m, 2H,
Ar-H), 3.89 (s, 3H, COCH3). LC–MS (m/z, %): 480
(M+1)+. Anal. Calcd for C25H13N5O4S: C, 62.89; H, 2.91;
N, 14.73. Found: C, 62.63; H, 2.73; N, 14.61.
2.4.8. (Z)-7-Isocyano-2-(4-methylbenzylidene)-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo
[1,5-a]pyridine-9-carbonitrile (4h)
White solid in a yield of 74%, mp 192–193 C; IR (KBr, cm1):
3030 (Ar-H), 1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz,
Synthesis and pharmacological evaluation 139DMSO-d6): d 7.80 (s, 1H, CH), 7.59–7.57 (m, 2H, Ar-H), 7.40–
7.33 (m, 3H, Ar-H), 7.18–7.17 (m, 4H, Ar-H), 2.34 (s, 3H,
CH3). LC–MS (m/z, %): 436 (M+1)
+. Anal. Calcd for
C24H13N5O2S: C, 66.58; H, 3.18; N, 16.27. Found: C, 66.20;
H, 3.01; N, 16.08.
2.4.9. (Z)-7-Isocyano-2-(4-isopropylbenzylidene)-3,6-dioxo-8-
phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo
[1,5-a]pyridine-9-carbonitrile (4i)
White solid in a yield of 72%, mp 210–211 C; IR (KBr, cm1):
3030 (Ar-H), 1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz,
DMSO-d6): d 7.80 (s, 1H, CH), 7.63–7.62 (m, 2H, Ar-H), 7.40–
7.25 (m, 5H, Ar-H), 7.17–7.15 (m, 2H, Ar-H), 2.87–2.70 (m,
1H, CH), 1.20 (d, 6H, CH3). LC–MS (m/z, %): 464
(M+1)+. Anal. Calcd for C26H17N5O2S: C, 67.71; H, 3.88;
N, 15.32. Found: C, 67.38; H, 3.70; N, 15.11.
2.4.10. (Z)-2-(4-(tert-Butyl)benzylidene)-7-isocyano-3,6-
dioxo-8-phenyl-3,6-dihydro-2H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (4j)
White solid in a yield of 75%, mp 201–202 C; IR (KBr, cm1):
3030 (Ar-H), 1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz,
DMSO-d6): d 7.80 (s, 1H, CH), 7.63–7.62 (m, 2H, Ar-H), 7.40–
7.25 (m, 5H, Ar-H), 7.17–7.15 (m, 2H, Ar-H), 1.35 (s, 9H,
CH3). LC–MS (m/z, %): 478 (M+1)
+. Anal. Calcd for
C27H19N5O2S: C, 68.23; H, 4.17; N, 14.72. Found: C, 67.91;
H, 4.01; N, 14.67.
2.5. 3-Hydroxy-7-isocyano-6-oxo-8-phenyl-2-
(substitutedphenyl(piperidin-1-yl)methyl)-6H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]-pyridine-9-carbonitrile (5a–j)
To a solution of (Z)-2-(4-substitutedbenzylidene)-7-isocyano-
3,6-dioxo-8-phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]-
triazolo[1,5-a]-pyridine-9-carbonitrile (4a–j) (2 mmol) in
tetrahydrofuran (20 mL) a solution of piperidine (3 mmol)
was added and the mixture was stirred for 6 h at room temper-
ature under the conditions of Michael addition reaction. The
crude product thus formedwas crystallized from benzene/cyclo-
hexane mixture to give products 5a–j in 65–80% yield.
2.5.1. 3-Hydroxy-7-isocyano-6-oxo-8-phenyl-2-
(phenyl(piperidin-1-yl)methyl)-6H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (5a)
Colorless crystals in a yield of 67%, mp 130–132 C; IR (KBr,
cm1): 3100 (O–H), 3030 (Ar-H), 2960 (C–H aliphatic), 1730
(C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6):
7.70–7.30 (m, 10H, Ar-H), 6.90 (s, 1H, CH), 3.7–3.22 (m,
4H, N(CH2)2), 1.7–1.4 (m, 6H, (CH2)3). LC–MS (m/z, %):
507 (M+1)+. Anal. Calcd for C28H22N6O2S: C, 66.93; H,
5.02; N, 16.95. Found: C, 66.39; H, 4.38; N, 16.59.
2.5.2. 2-((4-Chlorophenyl)(piperidin-1-yl)methyl)-3-hydroxy-
7-isocyano-6-oxo-8-phenyl-6H-thiazolo[30,20:2,3]
[1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (5b)
Colorless crystals in a yield of 70%, mp 159–160 C; IR (KBr,
cm1): 3180 (O–H), 3050 (Ar-H), 2940 (C–H aliphatic), 1730
(C‚O), 1600 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.80–7.20 (m, 9H, Ar-H), 6.80 (s, 1H, CH), 3.5–3.2 (m, 4H,
N(CH2)2), 1.6–1.4 (m, 6H, (CH2)3), LC–MS (m/z, %): 542(M+1)+. Anal. Calcd for C28H21ClN6O2S: C, 62.88; H,
4.36; N, 16.21. Found: C, 62.16; H, 3.91; N, 15.53.
2.5.3. 3-Hydroxy-7-isocyano-2-((4-nitrophenyl)(piperidin-1-
yl)methyl)-6-oxo-8-phenyl-6H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (5c)
Yellow crystals in a yield of 69%, mp 175–176 C; IR (KBr,
cm1): 3120 (O–H), 3030 (Ar-H), 2900 (C–H aliphatic), 1730
(C‚O), 1600 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.80–7.20 (m, 9H, Ar-H), 6.80 (s, 1H, CH), 3.45, 3.13 (m,
4H, N(CH2)2), 1.50 (m, 4H, (CH2)2), 1.33 (m, 2H, CH2),
LC–MS (m/z, %): 552 (M+1)+. Anal. Calcd for
C28H21N7O4S: C, 61.43; H, 4.29; N, 18.24. Found: C, 60.97;
H, 3.84; N, 17.78.
2.5.4. 3-Hydroxy-7-isocyano-2-((4-methoxyphenyl)(piperidin-
1-yl)methyl)-6-oxo-8-phenyl-6H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (5d)
Pale yellow crystals in a yield of 71%, mp 130–132 C; IR
(KBr, cm1): 3150 (O–H), 3030 (Ar-H), 2920 (C–H aliphatic),
1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.60–7.30 (m, 9H, Ar-H), 6.90 (s, 1H, CH), 3.65 (s, 3H,
OCH3), 3.62–3.20 (m, 4H, N(CH2)2), 1.6–1.4 (m, 6H,
(CH2)3), LC–MS (m/z, %): 537 (M+1)
+. Anal. Calcd for
C29H24N6O3S: C, 65.22; H, 4.98; N, 15.89. Found: C, 64.91;
H, 4.51; N, 15.66.
2.5.5. 2-((4-(Dimethylamino)phenyl)(piperidin-1-yl)methyl)-
3-hydroxy-7-isocyano-6-oxo-8-phenyl-6H-
thiazolo[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile
(5e)
Orange crystals in a yield of 75%, mp 182–183 C; IR (KBr,
cm1): 3150 (O–H), 3030 (Ar-H), 2920 (C–H aliphatic), 1730
(C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.70–6.60 (m, 9H, Ar-H), 6.90 (s, 1H, CH), 3.5–3.3 (m, 4H,
N(CH2)2), 2.90 (s, 6H, N(CH3)2), 1.6–1.30 (m, 4H, (CH2)3),
LC–MS (m/z, %): 550 (M+1)+. Anal. Calcd for
C30H27N7O2S: C, 65.83; H, 5.26; N, 18.13. Found: C, 65.56;
H, 4.95; N, 17.84.
2.5.6. 2-((4-Bromophenyl)(piperidin-1-yl)methyl)-3-hydroxy-
7-isocyano-6-oxo-8-phenyl-6H-
thiazolo[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile
(5f)
Pale yellow crtstals in a yield of 72%, mp 174–175 C; IR
(KBr, cm1): 3150 (O–H), 3030 (Ar-H), 2920 (C–H aliphatic),
1720 (C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.95–7.25 (m, 9H, Ar-H), 6.85 (s, 1H, CH), 3.65–3.25 (m, 4H,
N(CH2)2), 1.65–1.3 (m, 6H, (CH2)3), LC–MS (m/z, %): 587
(M+2)+. Anal. Calcd for C28H21BrN6O2S: C, 57.91; H,
4.05; N, 14.88. Found: C, 57.44; H, 3.62; N, 14.35.
2.5.7. Methyl4-((9-cyano-3-hydroxy-7-isocyano-6-oxo-8-
phenyl-6H-thiazolo[30,20:2,3]-[1,2,4]triazolo[1,5-a]pyridin-2-
yl)(piperidin-1-yl)methylbenzoate (5g)
Yellow crystals in a yield of 65%, mp 141–142 C; IR (KBr,
cm1): 3160 (O–H), 3050 (Ar-H), 1765 (OCO), 1720 (C‚O),
1590 (C‚N), 1H NMR (300 MHz, DMSO-d6): d 7.80–7.21
(m, 9H, Ar-H), 6.90 (s, 1H, CH), 3.90 (s, 3H, COCH3),
3.6–3.2 (m, 4H, N(CH2)2), 1.60–1.2 (m, 6H, (CH2)3), LC–
140 M. Suresh et al.MS (m/z, %): 565 (M+1)+. Anal. Calcd for C30H24N6O4S:
C, 64.25; H, 4.44; N, 15.32. Found: C, 63.82; H, 4.28; N,
14.86.
2.5.8. 3-Hydroxy-7-isocyano-6-oxo-8-phenyl-2-(piperidin-1-yl
(p-tolyl)methyl)-6H-thiazolo[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (5h)
Yellow crystals in a yield of 70%, mp 179–180 C; IR (KBr,
cm1): 3120 (O–H), 3030 (Ar-H), 2920 (C–H, aliphatic),
1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6):
d 7.75–7.20 (m, 9H, Ar-H), 6.75 (s, 1H, CH), 3.65–3.35 (m,
4H, N(CH2)2), 2.30 (s, 3H, CH3), 1.65–1.2 (m, 6H, (CH2)3),
LC–MS (m/z, %): 521 (M+1)+. Anal. Calcd for
C29H24N6O2S: C, 67.58; H, 4.97; N, 16.57. Found: C, 66.91;
H, 4.65; N, 16.14.
2.5.9. 3-Hydroxy-7-isocyano-2-((4-isopropylphenyl)
(piperidin-1-yl)methyl)-6-oxo-8-phenyl-6H-thiazolo-
[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile (5i)
Orange crystals in a yield of 72%, mp 139–140 C; IR (KBr,
cm1): 3150 (O–H), 3050 (Ar-H), 2920 (C–H, aliphatic),
1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6):
d 7.70–7.20 (m, 9H, Ar-H), 6.70 (s, 1H, CH), 3.67–3.25 (m,
4H, N(CH2)2), 2.80–2.70 (m, 1H, CH), 1.62–1.10 (m, 12H,
(CH3)2 and (CH2)3). LC–MS (m/z, %): 549 (M+1)
+. Anal.
Calcd for C31H28N6O2S: C, 68.23; H, 4.84; N, 15.92. Found:
C, 67.86; H, 5.14; N, 15.32.
2.5.10. 2-((4-(tert-Butyl)phenyl)(piperidin-1-yl)methyl)-3-
hydroxy-7-isocyano-6-oxo-8-phenyl-6H-
thiazolo[30,20:2,3][1,2,4]triazolo[1,5-a]pyridine-9-carbonitrile
(5j)
Pale yellow crystals in a yield of 80%, mp 165–166 C; IR
(KBr, cm1): 3200 (O–H), 3050 (Ar-H), 2960 (C–H aliphatic),
1730 (C‚O), 1590 (C‚N), 1H NMR (300 MHz, DMSO-d6): d
7.70–7.15 (m, 9H, Ar-H), 6.80 (s, 1H, CH), 3.65–3.20 (m, 4H,
N(CH2)2), 1.9–1.11 (m, 15H, (CH2)3 and (CH3)3). LC–MS (m/
z, %): 563 (M+1)+. Anal. Calcd for C32H30N6O2S: C, 68.76;
H, 5.69; N, 15.35. Found: C, 68.31; H, 5.37; N, 14.94.3. Results and discussion
The IR spectrum of (Z)-2-benzylidene-7-isocyano-3,6-dioxo-
8-phenyl-3,6-dihydro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-
a]pyridine-9-carbonitrile (4a) showed an absorption band at
3032 cm1 indicates the Ar-H stretching. The absorption
band at 1730 cm1 due to the presence of C‚O stretching
of the thiazole ring system. Other prominent absorption
band is observed at 1590 cm1 (C‚N). The 300 MHz 1H
NMR spectrum of compound 4a showed a singlet at d
8.20 integrating for one proton, which is attributed to the
benzylidene proton. The aromatic protons resonated as
three multiplets at d7.60–7.55, 7.45–7.33 and 7.19–7.17. Fur-
ther evidence for the formation of compound 4a was ob-
tained by recording its mass spectra. The mass spectrum
of compound 4a showed a molecular ion peak at m/z 422
(M+1)+, which is in consistent with its molecular formula
C23H11N5O2S. The characterization data of (Z)-2-(4-sub-
stitutedbenzylidene)-7-isocyano-3,6-dioxo-8-phenyl-3,6-dihy-
dro-2H-thiazolo-[30,20:2,3][1,2,4]triazolo[1,5-a]-pyridine-9-car-
bonitrile (4a–j) are given in Section 2.The IR spectrum of 3-hydroxy-7-isocyano-6-oxo-8-phenyl-
2-(phenyl(piperidin-1-yl)methyl)-6H-thiazolo-[30,20:2,3][1,2,4]
triazolo[1,5-a]pyridine-9-carbonitrile (5a) was showed an
absorption band at 3100 cm1, 3030 cm1 indicated the O–
H, Ar-H stretching. The absorption band appeared at
1730 cm1 due to the presence of C‚O stretching of the thiaz-
olo ring system. Other prominent absorption band was ob-
served at 1590 cm1 (C‚N). The 300 MHz 1H NMR
spectrum of compound 5a showed a singlet at d 6.90 integrat-
ing for one proton, which was attributed to the benzylidene
proton. The aromatic protons resonated as multiplet at d
7.70–7.30 and 3.7–1.4 (m, 10H, 5CH2 of piperidine). Further
evidence for the formation of compound 5a was obtained by
recording its mass spectra. The mass spectrum of compound
5a showed a molecular ion peak at m/z 507 (M+1)+, which
was in consistent with its molecular formula C28H22N6O2S.
The characterization data of 3-hydroxy-7-isocyano-6-oxo-8-
phenyl-2-(substitutedphenyl-(piperidin-1-yl)-methyl)-6H-thiaz-
olo-[30,20:2,3][1,2,4]triazolo[1,5-a]-pyridine-9-carbonitrile (5a–
j) were given in Section 2.4. Pharmacological studies
4.1. Antibacterial activity
The newly synthesized compounds were screened for their anti-
bacterial activity against Escherichia coli, Staphylococcus aur-
eus, Pseudomonas aeruginosa, Streptococcus pyogenes and
Klebsiella pneumoniae (recultured) bacterial strains by disc dif-
fusion method (Cruickshank et al., 1975; Collins, 1976). The
investigation of antibacterial screening data revealed that all
the tested compounds showed moderate to good bacterial inhi-
bition. The compounds 4a, 4b, 4e, 4f, 4i, 4j, 5a, 5b, 5d, 5g, 5i
and 5j showed very good activity against all the bacterial
strains.
4.2. Antifungal studies
Newly prepared compounds were screened for their antifungal
activity against Aspergillus ﬂavus, Aspergillus fumigatus, Can-
dida albicans, Penicillium marneffei and Trichophyton mentag-
rophytes (recultured) in DMSO by serial plate dilution
method (Khan, 1997; Varma, 1998). The antifungal screening
data showed moderate to good activity. Compounds 4a, 4c,
4f, 4i, 4j, 5a, 5c, 5f, 5i and 5j emerged as very active against
all the fungal strains.5. Pharmacological assay
5.1. Antibacterial assay
A standard inoculum (1–2 · 107 c.f.u/cm3 0.5 McFarland stan-
dards) was introduced on to the surface of sterile agar plates,
and a sterile glass spreader was used for even distribution of
the inoculum. The discs measuring 6.25 mm in diameter were
prepared from Whatman No.1 ﬁlter paper and sterilized by
dry heat at 140 C for 1 h. The sterile disc previously soaked
in a known concentration of the test compounds were placed
in nutrient agar medium. Solvent and growth controls were
kept. The plates were inverted and incubated for 24 h at
37 C. The inhibition zones were measured and compared with
Table 1 Antibacterial activity of thiazolotriazinoes (4a–j) and (5a–j).
Compound no. Staphylococcus aureus Escherichia coli Pseudomonas aeruginosa Klebsiella pneumoniae Streptococcus pyogenes
4a 20 (6.25) 25 (6.25) 29 (6.25) 18 (6.25) 23 (6.25)
4b 23 (6.25) 28 (6.25) 30 (6.25) 18 (6.25) 21 (6.25)
4c 10 (12.5) – – 17 (6.25) 11 (6.25)
4d 8 (25) 23 (6.25) 9 (25) – 8 (12.5)
4e 22 (6.25) 27 (6.25) 32 (6.25) 20 (6.25) 24 (6.25)
4f 21 (6.25) 29 (6.25) 32 (6.25) 20 (6.25) 23 (6.25)
4g 10 (12.5) 15 (25) – – 17 (12.5)
4h 12 (12.5) – 21 (6.25) – 8 (25)
4i 21 (6.25) 24 (6.25) 29 (6.25) 19 (6.25) 23 (6.25)
4j 21 (6.25) 26 (6.25) 32 (6.25) 21 (6.25) 24 (6.25)
5a 22 (6.25) 26 (6.25) 28 (6.25) 21 (6.25) 24 (6.25)
5b 21 (6.25) 28 (6.25) 30 (6.25) 20 (6.25) 22 (6.25)
5c –- 10 (6.25) – – 10 (6.25)
5d 23 (6.25) 26 (6.25) 29 (6.25) 21 (6.25) 22 (6.25)
5e 8 (25) – – 10 (6.25) 12 (12.5)
5f – 8 (12.5) 10 (12.5) 14 (12.5) –
5g 19 (6.25) 28 (6.25) 27 (6.25) 21 (6.25) 20 (6.25)
5h 10 (12.5) – 12 (6.25) – 8 (25)
5i 20 (6.25) 27 (6.25) 28 (6.25) 20 (6.25) 22 (6.25)
5j 22 (6.25) 28 (6.25) 31 (6.25) 21 (6.25) 24 (6.25)
Standarda 24 (6.25) 30 (6.25) 33 (6.25) 23 (6.25) 25 (6.25)
– indicates bacteria is resistant to the compounds at >100 lg/mL, MIC values are given in brackets. MIC (lg/mL) = minimum inhibitory
concentration, i.e., lowest concentration to completely inhibit bacterial growth. Zone of inhibition in mm.
a Ciproﬂoxacin was used as standard.
Table 2 Antifungal activity of thiazolotriazinoes (4a–j) and (5a–j).
Compound no. Aspergillus fumigatus Aspergillus ﬂavus Trichophyton mentagrophytes Penicillium marneﬀei Candida albicans
4a 22 (6.25) 22 (6.25) 25 (6.25) 22 (6.25) 20 (6.25)
4b 8 (25) – 12 (12.5) – 17 (6.25)
4c 22 (6.25) 20 (6.25) 22 (6.25) 25 (6.25) 17 (6.25)
4d 15 (6.25) – 7 (25) 21 (6.25) 18 (6.25)
4e 5 (25) 18 (6.25) – 12 (12.5) 17 (6.25)
4f 24 (6.25) 21 (6.25) 21 (6.25) 23 (6.25) 18 (6.25)
4g 11 (12.5) 12 (25) – – 14 (12.5)
4h 9 (25) – 12 (12.5) 9 (25) 10 (12.5)
4i 22 (6.25) 19 (6.25) 20 (6.25) 23 (6.25) 19 (6.25)
4j 21 (6.25) 26 (6.25) 32 (6.25) 21 (6.25) 24 (6.25)
5a 22 (6.25) 22 (6.25) 25 (6.25) 22 (6.25) 20 (6.25)
5b 8 (25) – 12 (12.5) – 17 (6.25)
5c 22 (6.25) 20 (6.25) 22 (6.25) 25 (6.25) 17 (6.25)
5d 15 (6.25) – 7 (25) 21 (6.25) 18 (6.25)
5e 5 (25) 18 (6.25) – 12 (12.5) 17 (6.25)
5f 24 (6.25) 21 (6.25) 21 (6.25) 23 (6.25) 18 (6.25)
5g 11 (12.5) 12 (25) – – 14 (12.5)
5h 9 (25) – 12 (12.5) 9 (25) 10 (12.5)
5i 22 (6.25) 19 (6.25) 20 (6.25) 23 (6.25) 19 (6.25)
5j 21 (6.25) 26 (6.25) 32 (6.25) 21 (6.25) 24 (6.25)
Standardb 25 (6.25) 21 (6.25) 23 (6.25) 25 (6.25) 19 (6.25)
– indicates fungus is resistant to the compounds at >100 mg/mL, MIC values are given in brackets. MIC (mg/mL) = minimum inhibitory
concentration, i.e., lowest concentration to completely inhibit fungal growth. Zone of inhibition in mm.
b Amphotericin was used as standard.
Synthesis and pharmacological evaluation 141the controls. Minimum inhibitory concentration (MIC) was
determined by broth dilution technique. The nutrient broth,
which contained logarithmic serially twofold diluted amount
of test compound and controls were inoculated with approxi-
mately 5 · 105 c.f.u of actively dividing bacteria cells. The cul-
tures were incubated for 24 h at 37 C and the growth wasmonitored visually and spectrophotometrically. The lowest
concentration (highest dilution) required to arrest the growth
of bacteria was regarded as minimum inhibitory concentra-
tions (MIC). Ciproﬂoxacin was used as a standard drug. The
diameter of the zone of inhibition and minimum inhibitory
concentration values are given in Table 1.
142 M. Suresh et al.5.2. Antifungal assay
Sabouraud’s agar media was prepared by dissolving 1 g pep-
tone, 4 g D-glucose, and 2 g agar in 100 cm3 distilled water,
and adjusting pH to 5.7 using buffer. Normal saline was used
to make a suspension of spore of fungal strain for lawning. A
loop full of particular fungal strain was transferred to 3 cm3
saline to get a suspension of corresponding species. 20 cm3 of
agar media was poured in to each Petri dish. Excess of suspen-
sion was decanted and the plates were dried by placing in a
incubator at 37 C for 1 h. Using an agar punch, wells were
made and each well was labeled. A control was also prepared
in triplicate and maintained at 37 C for 3–4 d. The inhibition
zones in diameter were measured and compared with the con-
trols. The Nutrient Broth, which contained logarithmic serially
twofold diluted amount of test compound and controls was
inoculated with approximately 1.6–6 · 104 c.f.u cm3. The cul-
tures were incubated for 48 h at 35 C and the growth was
monitored. The lowest concentration (highest dilution) re-
quired to arrest the growth of fungus was regarded as mini-
mum inhibitory concentrations (MIC). Amphotericin B was
used as the standard drug. The diameter of zone of inhibition
and minimum inhibitory concentration values are given in Ta-
ble 2.
6. Conclusion
The investigation of antibacterial screening data reveals that
among the 20 compounds screened, seven compounds showed
good bacterial and fungal inhibition almost equivalent to that
of standard.Acknowledgments
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